FDA’s Unapproved Drugs Policy Draws Legal, Regulatory Responses From Lannett, To Little Success

Generic drug maker Lannett Co. is taking a two-pronged approach in responding to FDA’s unapproved drugs initiative, seeking regulatory approval of a previously unapproved opioid product while simultaneously suing the agency in federal court.